Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsThe authors found that the immune checkpoint ligand PD-L2 is robustly expressed in patient samples of ovarian cancers and other malignancies exhibiting suboptimal response to immune checkpoint blockade (ICB) but not in cancers that are ICB sensitive.
[Clinical Cancer Research]
6445212 MAVBTKLH items 1 apa 0 default asc 1 162500 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-07f2bbc6e52f1dc516c4fb2166d78516%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22MAVBTKLH%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Miao%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMiao%2C%20Y.%20R.%2C%20Thakkar%2C%20K.%20N.%2C%20Qian%2C%20J.%2C%20Kariolis%2C%20M.%20S.%2C%20Huang%2C%20W.%2C%20Nandagopal%2C%20S.%2C%20Yang%2C%20T.%20T.%20C.%2C%20Diep%2C%20A.%20N.%2C%20Cherf%2C%20G.%20M.%2C%20Xu%2C%20Y.%2C%20Moon%2C%20E.%20J.%2C%20Xiao%2C%20Y.%2C%20Alemany%2C%20H.%2C%20Li%2C%20T.%2C%20Yu%2C%20W.%2C%20Wei%2C%20B.%2C%20Rankin%2C%20E.%20B.%2C%20%26amp%3B%20Giaccia%2C%20A.%20J.%20%282021%29.%20Neutralization%20of%20PD-L2%20is%20Essential%20for%20Overcoming%20Immune%20Checkpoint%20Blockade%20Resistance%20in%20Ovarian%20Cancer.%20%3Ci%3EClinical%20Cancer%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-0482%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-0482%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DMAVBTKLH%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neutralization%20of%20PD-L2%20is%20Essential%20for%20Overcoming%20Immune%20Checkpoint%20Blockade%20Resistance%20in%20Ovarian%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu%20Rebecca%22%2C%22lastName%22%3A%22Miao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaushik%20N.%22%2C%22lastName%22%3A%22Thakkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jin%22%2C%22lastName%22%3A%22Qian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihalis%20S.%22%2C%22lastName%22%3A%22Kariolis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saravanan%22%2C%22lastName%22%3A%22Nandagopal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teddy%20Tat%20Chi%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anh%20N.%22%2C%22lastName%22%3A%22Diep%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerald%20Maxwell%22%2C%22lastName%22%3A%22Cherf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eui%20Jung%22%2C%22lastName%22%3A%22Moon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yiren%22%2C%22lastName%22%3A%22Xiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haizea%22%2C%22lastName%22%3A%22Alemany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiane%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wenhua%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bo%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erinn%20B.%22%2C%22lastName%22%3A%22Rankin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amato%20J.%22%2C%22lastName%22%3A%22Giaccia%22%7D%5D%2C%22abstractNote%22%3A%22Purpose%3A%20Ovarian%20cancer%20represents%20a%20major%20clinical%20hurdle%20for%20immune%20checkpoint%20blockade%20%28ICB%29%2C%20with%20reported%20low%20patient%20response%20rates.%20We%20found%20that%20the%20immune%20checkpoint%20ligand%20PD-L2%20is%20robustly%20expressed%20in%20patient%20samples%20of%20ovarian%20cancers%20and%20other%20malignancies%20exhibiting%20suboptimal%20response%20to%20ICB%20but%20not%20in%20cancers%20that%20are%20ICB%20sensitive.%20Therefore%20we%20hypothesize%20that%20PD-L2%20can%20facilitate%20immune%20escape%20from%20ICB%20through%20incomplete%20blockade%20of%20the%20PD-1%20signaling%20pathway.%20Experimental%20Design%3A%20We%20engineered%20a%20soluble%20form%20of%20the%20PD-1%20receptor%20%28sPD-1%29%20capable%20of%20binding%20and%20neutralizing%20both%20PD-L2%20and%20PD-L1%20with%20x200%20and%20x10%2C000%20folds%20improvement%20in%20binding%20affinity%20over%20wild-type%20PD-1.%20Leading%20to%20superior%20inhibition%20of%20ligand-mediated%20PD-1%20activities.%20Results%3A%20Both%20In%20vitro%20and%20in%20vivo%20analyses%20performed%20in%20this%20study%20demonstrated%20that%20the%20high-affinity%20sPD-1%20molecule%20is%20superior%20at%20blocking%20both%20PD-L1%20and%20PD-L2%20mediated%20immune%20evasion%20and%20reducing%20tumor%20growth%20in%20immune-competent%20murine%20models%20of%20ovarian%20cancer.%20Conclusions%3A%20The%20data%20presented%20in%20this%20study%20provides%20justification%20for%20using%20a%20dual%20targeting%2C%20high-affinity%20sPD-1%20receptor%20as%20an%20alternative%20to%20PD-1%20or%20PD-L1%20therapeutic%20antibodies%20for%20achieving%20superior%20therapeutic%20efficacy%20in%20cancers%20expressing%20both%20PD-L2%20and%20PD-L1.%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-20-0482%22%2C%22ISSN%22%3A%221078-0432%2C%201557-3265%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fclincancerres.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F05%5C%2F18%5C%2F1078-0432.CCR-20-0482%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-05-20T18%3A22%3A48Z%22%7D%7D%5D%7D
Miao, Y. R., Thakkar, K. N., Qian, J., Kariolis, M. S., Huang, W., Nandagopal, S., Yang, T. T. C., Diep, A. N., Cherf, G. M., Xu, Y., Moon, E. J., Xiao, Y., Alemany, H., Li, T., Yu, W., Wei, B., Rankin, E. B., & Giaccia, A. J. (2021). Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-0482 Cite
